Invited commentary.
Chambers
David J
DJ
Cardiac Surgical Research, The Rayne Institute (King's College London), Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, London, SE1 7EH United Kingdom. chambers@kcl.ac.uk <chambers@kcl.ac.uk>
D000818:Animals; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors*; D000071679:Glycogen Synthase Kinase 3 beta; D006019:Glycolysis; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000201:enzymology*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000032:analysis; D011817:Rabbits
D047428:Protein Kinase Inhibitors; D000071679:Glycogen Synthase Kinase 3 beta; D051057:Proto-Oncogene Proteins c-akt; D038362:Glycogen Synthase Kinase 3